Honolulu, Hawaii 2021-08-05 11:12:30 –
Tampa, Florida (WFLA) — Pharmaceutical company Moderna has seen antibody levels in the COVID-19 vaccine decline over time, with double doses in winter to protect against viral variants. I think I will need a booster vaccination before.
“We believe that increased infectivity due to delta, non-pharmaceutical intervention (NPI) malaise, and seasonal effects (movement indoors) will lead to increased breakthrough infections in vaccinated individuals. ” The company said in its second quarter earnings announcement Thursday.
According to the presentation, Moderna’s COVID-19 shot was about 93% effective 6 months after the second dose, but was expected to reduce antibody levels and affect vaccine efficacy. rice field.
“Given this intersection, we think it’s likely that we’ll need a dose 3 booster before winter,” the presentation said.
The COVID-19 vaccine is Moderna’s only commercially approved product. We are also developing several vaccines aimed at preventing influenza, Zika fever and HIV, among other viruses. According to the website, they are all in the early stages of clinical trials.
The company is also testing potential booster shots of the COVID-19 vaccine.
Moderna’s COVID-19 vaccine helped boost vaccine developers to profits with second-quarter sales of over $ 4 billion.
The announcement of Moderna came after pharmaceutical giant Pfizer Inc. stated that the COVID-19 vaccine remained effective after the second vaccination and became a top seller. This has generated almost half of the company’s revenue. This is $ 7.84 billion from direct sales and revenue sharing with partner BioNTech in Germany.
Moderna’s COVID-19 vaccine is urgently licensed for use in more than 50 countries.
The Associated Press contributed to this report.
Moderna says COVID-19 vaccine booster will likely be needed before winter Source link Moderna says COVID-19 vaccine booster will likely be needed before winter